Evidence map›Paper›PMID 33841549›Full record

ArticleIranian journal of pharmaceutical research : IJPR2020

Efficacy and Side Effects of Combined Capecitabine Plus Intensity Modulated Radiotherapy as an Effective Adjuvant Therapy for Gastric Cancers.

Jie Fu, Chun-Yan Wang, Chun-Gang Wang, Hong-Ling Li, Xiao-Jing Yang, Yi Sun, Yu-Hui Shao, Li-Hua Zhang, Xin-Miao Yang, Xiu-Long Zhang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of pharmaceutical research : IJPR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Jie FuDepartment of Radiation Oncology, Shanghai Jiao Tong University Affiliated Six People's Hospital, No 600, Yishan Road, Shanghai 200233, China.
Chun-Yan WangDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200310, China.
Chun-Gang WangDepartment of Radiation Oncology, Shanghai Jiao Tong University Affiliated First People's Hospital, No 100, Haining Road, Shanghai 200233, China.
Hong-Ling LiDepartment of Radiation Oncology, Shanghai Jiao Tong University Affiliated Six People's Hospital, No 600, Yishan Road, Shanghai 200233, China.
Xiao-Jing YangDepartment of Radiation Oncology, Shanghai Jiao Tong University Affiliated Six People's Hospital, No 600, Yishan Road, Shanghai 200233, China.
Yi SunDepartment of Radiation Oncology, Shanghai Jiao Tong University Affiliated Six People's Hospital, No 600, Yishan Road, Shanghai 200233, China.
Yu-Hui ShaoDepartment of Radiation Oncology, Shanghai Jiao Tong University Affiliated Six People's Hospital, No 600, Yishan Road, Shanghai 200233, China.
Li-Hua ZhangDepartment of Radiation Oncology, Shanghai Jiao Tong University Affiliated Six People's Hospital, No 600, Yishan Road, Shanghai 200233, China.
Xin-Miao YangDepartment of Radiation Oncology, Shanghai Jiao Tong University Affiliated Six People's Hospital, No 600, Yishan Road, Shanghai 200233, China.
Xiu-Long ZhangDepartment of Radiation Oncology, Shanghai Jiao Tong University Affiliated Six People's Hospital, No 600, Yishan Road, Shanghai 200233, China.
Shanghai Sixth People's Hospital · CNZero to Three · USShanghai First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aims to evaluate the clinical outcomes and the toxicities associated with intensity modulated radiotherapy (IMRT) administered in combination with capecitabine for gastric cancer. This study was conducted between July 2009 and October 2011, and included 31 patients (23 female and eight male patients; mean age: 57 years old) with pathologically confirmed gastric cancer (pathological staging T3 or T4 or positive lymph node). All patients underwent D2 surgery and adjuvant chemoradiotherapy, followed by combined treatment with IMRT and capecitabine. All patients received follow-up examinations every 3-6 months by physical examination, magnetic resonance imaging (MRI), and assays for tumor markers. The Kaplan-Meier method was used to calculate the rates for locoregional control (LRC) and disease-free survival (DFS). Only two patients could not complete the planned treatment regimen. Patients treated with IMRT and capecitabine tolerated their treatment well, and displayed few significant side effects. The mean follow-up, disease-free survival (DFS) and survival times were 33.0, 27.5, and 32.9 months, respectively.This study confirmed that the combined administration of IMRT and capecitabine can be used as an adjuvant therapy for gastric cancer patients, with few toxic side effects.

Indexed as

Adjuvant therapyCapecitabineGastric cancerIntensity modulated radiotherapy (IMRT)Side effects

Identifiers

PMID33841549
PMCPMC8019857
OpenAlexW3153132017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.